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The laboratory diagnosis of Lyme disease is currently dependent on the detection of IgM and IgG antibodies
against Borrelia burgdorferi, the causative agent of the disease. The signiﬁcance of serum IgA against
B. burgdorferi remains unclear. The production of intrathecal IgA has been noted in patients with the late Lyme
disease manifestation, neuroborreliosis, but production of antigen-speciﬁc IgA during early disease has not
been evaluated. In the current study, we assessed serum IgA binding to the B. burgdorferi peptide antigens, C6,
the target of the FDA-cleared C6 EIA, and FlaB(211-223)-modVlsE(275-291), a peptide containing a Borrelia ﬂa-
gellin epitope linked to a modiﬁed VlsE sequence, in patients with early and late Lyme disease. Speciﬁc IgA was
detected in 59 of 152 serum samples (38.8%) from early Lyme disease patients. Approximately 50% of early Lyme
disease patients who were seropositive for peptide-speciﬁc IgM and/or IgG were also seropositive for peptide-
speciﬁc IgA. In a subpopulation of patients, high peptide-speciﬁc IgA could be correlated with disseminated dis-
ease, deﬁned asmultiple erythemamigrans lesions, and neurological disease complications. These results suggest
that there may be an association between elevated levels of antigen-speciﬁc IgA and particular disease manifes-
tations in some patients with early Lyme disease.
©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Lyme disease (LD) is a tick-transmitted bacterial infection caused by
spirochetes of the genus Borrelia, including B. burgdorferi (Bb), B. garinii,
and B. afzelii. It is endemic in parts of North America and Europe. The
skin lesion, erythemamigrans (EM), is a classic marker of early infection
and present in ~80% of acutely diagnosed individuals (Steere et al.,
1998). It is the only speciﬁc clinical marker for LD (Wormser et al.,
2006; Steere et al., 1998) and in regions endemic for LD, presentation
with EM is considered diagnostic. Other clinical manifestations are non-
speciﬁc and are found in a wide variety of other illnesses. Unlike most
bacterial infections where culture is the major diagnostic method, cul-
ture of Bb has proven to be ineffective for routine use (Centers for
Disease Control and Prevention (CDC), 1995). Therefore, the laboratory
diagnosis of LD is based on indirect methods, primarily the serological
detection of IgM and IgG antibodies against Bb (Schriefer, 2015). In
North America, seroreactivity is tested using the two-tier paradigm de-
lineated by the CDC, consisting of a ﬁrst-tier EIA and a second-tier im-
munoblot measuring IgM and IgG (Centers for Disease Control and
Prevention (CDC), 1995; Craven et al., 1996).
The two-tier paradigm has excellent speciﬁcity; however, low sensi-
tivity is a signiﬁcant issue in early disease. The sensitivity of current IgM
and IgG LD assays during early disease seldom exceeds 50% (Stanek
et al., 2012; Nowakowski et al., 2001; Gomes-Solecki et al., 2001,
2002; Liang et al., 2004;Wormser et al., 1999; Bacon et al., 2003; Coulter
et al., 2005; Robertson et al., 2000). For those patients that either do not
develop an EM, or present with an atypical EM that can bemistaken for
a rash, there is a signiﬁcant need for sensitive and accurate laboratory
diagnostics for Borrelia infection (Schutzer et al., 1999). Early interven-
tion is paramount for ensuring good patient outcomes and preventing
development of subsequent late stage disease that can result in perma-
nent damage to neurological and musculoskeletal systems (Aguero-
Rosenfeld et al., 2005). That Bb induces the generation of speciﬁc IgM
and IgG antibodies is well documented. However, the role of serum
anti-Bb IgA in early LD patients has not been deﬁned.
IgA is the second most common antibody isotype in human blood,
after IgG. Unlike polymeric IgA produced at mucosal surfaces, human
serum IgA is principally monomeric (subclass IgA1). Monomeric
serum IgA is not secreted across the mucosal barrier and has a half-life
of 4.5–6 days in peripheral blood (Schaller et al., 2008). The role of
serum IgA in immunity has yet to be clearly deﬁned. With respect to
LD, one publication that focused on the development of Lyme arthritis
and cryoglobulin IgM in 48 untreated EM patients had incidentally
noted that circulating anti-Borrelia IgA and IgG tended to move con-
versely to IgM (Steere et al., 1979). Other studies associating IgA and
LDhave concentrated on the intrathecal production of anti-Bb IgA in pa-
tientswith neuroborreliosis (Steere et al., 1990; Kaiser, 1998; Jesse et al.,
2011; Schwenkenbecher et al., 2017; Kowarik et al., 2012; Roberg et al.,
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1995; Kaiser, 1998; Jesse et al., 2011; Schwenkenbecher et al., 2017;
Kowarik et al., 2012). No study has speciﬁcally addressed the presence
of circulating anti-Borrelia IgA in early LD. In the present study, we
found that approximately one-third of patients presenting with early
LD had circulating IgA antibodies speciﬁc for Borrelia peptide antigens.
We utilized peptides that were highly speciﬁc to Bb to limit the detec-
tion of cross-reactive IgA induced by a response to a non-Borrelia infec-
tion. Our results suggest that there could be a potential role for serum
IgA detection in the laboratory diagnosis of LD.
2. Materials and Methods
2.1. Serum Samples
We performed a retrospective analysis of Bb-speciﬁc IgA in serum
from patients presenting with early LD (n= 152) and in patients with
Lyme arthritis (late LD) (n = 19). Sera from patients with early LD
were collected as a convenience series; that is, patients were recruited
from populations presenting to seasonal LD clinics (Table 1) typically
with one or more EM lesions and receiving a clinical diagnosis of early
LD. For patients included in this study that did not present with an
EM, diagnosis was supported by clinical presentation and positive stan-
dard serology (Table S1 and S2). All collection sites (Table 1) are in re-
gions endemic for LD, and sera were obtained during LD season,
which runs from mid-spring to mid-fall. Sera from Lyme arthritis pa-
tients were collected from patients upon ﬁrst clinical presentation to
the Gundersen Lutheran Medical Center in LaCrosse, WI; diagnosis
was made based on clinical presentation, all had joint swelling and a
positive Lyme serology. All serawere collected at the time of initial diag-
nosis with consent and under institutional review board (IRB) approval
from the relevant institutions listed in Table 1. All of the samples were
de-identiﬁed before being provided to us; experiments were conducted
without prior knowledge of clinical symptoms beyond a diagnosis of
early Lyme disease. For a limited number of samples, presented in
Tables S1 and S2, alphanumeric coding allowed access to de-identiﬁed
clinical data associated with the sample.
To deﬁne the cutoff (CO) values for equivocal and positive antibody
levels we assessed antibody binding in sera from healthy individuals
collected in both LD endemic and nonendemic areas. We deﬁned posi-
tive levels of antibody as a mean absorbance of three replicate wells
N3 SD from the mean of the nonendemic healthy controls; equivocal
levels were deﬁned as greater than 2 SD but less than 3SD from the
mean, and negative levels were deﬁned as b2 SD from the mean. The
CO values for IgA positive detection were calculated to be Absor-
bance(450–570) 1.769 (0.749 + 3 * 0.340) and Absorbance(450–570)
0.920 (0.423 + 3 * 0.166) for C6 and FlaB-mV, respectively. The CO
values for IgA equivocal detection were calculated to be Absor-
bance(450–570) 1.428 (0.749 + 2 * 0.340) and Absorbance(450–570)
0.754 (0.423 + 3 * 0.166) for C6 and FlaB-mV, respectively. Endemic
healthy donors were collected from Long Island, NY, an area where se-
roconversion was recorded at a rate of ~12% per year (Ginsberg,
2005). These sera were utilized as a separate negative healthy control.
Sera from patients with rheumatoid arthritis (RA), ﬁbromyalgia, or
syphilis were used as negative disease controls for speciﬁcity in this
assay. RA sera are used as negative disease controls because joint de-
struction and large joint inﬂammation are also observed in LD, while
syphilis sera serve as controls for an infectious disease caused by a relat-
ed spirochete, Treponema pallidum. Fibromyalgia sera are used as con-
trols because the disorder is marked by diffuse nonspeciﬁc symptoms
that are sometimes misinterpreted as early LD. All sera were aliquoted
and stored at −80 °C. For the study, individual aliquots were moved
to−20 °C, and freeze-thaw cycles were kept to a minimum.
2.2. Peptide ELISA
Peptide antigens, C6 (CMKKDDQIAAAIALRGMAKDGKFAVK) and
FlaB(211-223)-modVlsE(275-291) (FlaB-mV) (CVQEGVQQEGAQQ
PGGGMKKNDQIVAAIALRGVA) were synthesized by LifeTein (Somerset,
NJ). C6 is derived from theBbmembrane protein VlsE, and is the antigen
target in the FDA-cleared C6 ﬁrst-tier EIA. For these studieswe utilized a
synthesized C6 peptide (Gomes-Solecki et al., 2007) and not the com-
mercially available C6 assay. FlaB-mV is a previously described peptide
(Lahey et al., 2015) from the central portion of the Bb ﬂagellin protein
linked to amodiﬁed VlsE sequence. This sequence is altered to represent
a consensus sequence found in VlsE among different Borrelia strains to
minimize the impact of sequence variability on antibodybinding. ELISAs
for IgA, IgM, and IgG binding to peptides were performed as previously
described (Arnaboldi et al., 2013) using 10 μg/ml of peptide and (HRP)-
labeled goat anti-human IgA, IgM, and IgG (Southern Biotech, Birming-
ham, AL) as detecting antibodies at 1:15,000, 1:8000, and 1:5000 dilu-
tions, respectively.
Table 1
Patient serum samples.
Patient health status Obtained from Number Region obtained Lyme disease prevalence
Early Lyme diseasea New York Medical Collegeb 94 Northeast (New York) Endemic
Stony Brook Universityc 20 Northeast (New York) Endemic
Gundersen-Lutheran Medical Centerd 38 Upper Midwest (Wisconsin) Endemic
Late Lyme Diseasee (Lyme arthritis) Gundersen-Lutheran Medical Centerd 19 Upper Midwest (Wisconsin) Endemic
Healthy individuals Creative Testing Solutionsf,g 64 New Mexico Nonendemic
Bioreclamation, LLCg,h 40 Southern California Nonendemic
Stony Brook Universityc,i 35 Northeast (New York) Endemic
Rheumatoid arthritisj Bioreclamation, LLCg 53 Northeast Endemic
Syphilisk Bioreclamation, LLCg 34 Northeast Endemic
Fibromyalgia Bioreclamation, LLCg 16 Northeast Endemic
a Sera were collected from patients at their initial presentation to Lyme disease clinics.
b Located in Westchester, NY.
c Located in Long Island, NY.
d Located in LaCrosse, WI.
e Sera were collected from patients upon ﬁrst clinical presentation with swollen joints.
f Tempe, AZ.
g Sera were commercially purchased.
h Westbury, NY.
i Collected from healthy individuals working at the Fire Island National Seashore as part of a Lyme disease surveillance study in Long Island, NY (through Stony Brook University).
j Rheumatiod factor status unknown.
k Syphilis patients had a positive Rapid Plasma Reagin test and anti-treponemal antibody.
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2.3. Data Analysis
Statistical analyses were performed using Prism 6.0 (Graphpad, La
Jolla, CA). Comparisons of antibody binding absorbances between
groups (Fig. 1) were performed using a Kruskal-Wallis ANOVA followed
by a Dunn's multiple comparison post-test. Categorical data was ana-
lyzed using a Fisher's exact test with a two-tailed p value. Sensitivity,
speciﬁcity, and likelihood ratiowere calculated from contingency tables
by Prism 6.0.
3. Results
3.1. IgA Seropositive Patients Represent One-third of the LD Infected
Population
We assessed the prevalence of Bb-speciﬁc IgA in patients presenting
with early LD and in patients with Lyme arthritis (late LD). IgA binding
to either C6 or FlaB-mV peptides in early and late LD was signiﬁcantly
higher than in the healthy control or the disease control groups
(Fig. 1). Positive levels of IgA to FlaB-mV were observed in 53/152
(34.9%) early LD sera while positive levels of C6 were observed in 43/
152 (28.3%) early LD sera (Table 2). Positive levels of IgA to either pep-
tide were observed in 59/152 (38.8%) early LD patient serum samples
(Table 2),while the levels of IgAwere negligible in both healthy anddis-
ease control populations (Table 2). Of 242 combined healthy and dis-
ease control patients assayed, positive levels of IgA were only
observed in 3 sera for FlaB-mV (3/242, 1.24%) and 4 sera for C6 (4/
242, 1.65%) (Table 2). Positive levels of IgA occurred signiﬁcantly more
often in patients with early LD compared to each healthy and disease
control group for both C6 and FlaB-mV (p b 0.05) (Table 2). For the 19
late Lyme patients, 6 sera had positive levels of IgA to FlaB-mV (6/19,
31.6%) and 3 sera had positive levels for C6 (3/19, 15.8%) (Table 2). Pos-
itive IgA levels to FlaB-mV occurred signiﬁcantly more often in late LD
patients compared to each control group (p b 0.05), while positive IgA
levels to C6 were only signiﬁcant when compared with nonendemic
healthy control patients (p b 0.05).
The sensitivity and speciﬁcity of both C6 and FlaB-mV for identifying
positive samples were determined by comparing peptide-speciﬁc IgA
levels in early LD patients to those in all negative control groups
(Table 3). FlaB-mV demonstrated a slightly higher speciﬁcity and sensi-
tivity in the diagnosis of LD compared to C6 [FlaB-mV speciﬁcity: 98.8%
and sensitivity: 34.9% vs. C6 speciﬁcity: 98.4% and sensitivity: 28.3%
(Table 3)]. FlaB-mV also had a higher likelihood ratio (LR) than C6
(Table 3), indicating that there is a higher probability of obtaining true
positives than there are false positives using FlaB-mV exclusively. Over-
all, FlaB-mV functioned moderately better as an antigen target than C6
for IgA detection in Lyme patients.
3.2. Relationship Between anti-Borrelia IgG, IgM, and IgA
Anti-Borrelia IgM and IgG titers depend on the amount of time
elapsed between bacterial transmission and when the patient seeks
medical attention. As with most infections, higher IgM titers are associ-
atedwith recent infection,while higher IgG titers are indicative of either
a longer duration of infection or preexisting immunity due to a past ex-
posure/infection. Itwould be assumed that the IgA responsewouldmir-
ror the same pattern as IgG (Steere et al., 1979). However, the timing of
the serum IgA response in LD has not, to our knowledge, been well-
deﬁned.
To assess the relationship between anti-Borrelia IgG, IgM, and IgA,
we also assessed IgM and IgG binding to C6 and FlaB-mV. As some
serawere consumed fully, we performed ELISAs for IgM and IgG binding
to both peptides for only 133 of the 152 LD serum samples. None of the
patient sera had positive levels of only IgA to either peptide; however, 2
different patient sera had equivocal levels of IgA, one to C6 and the other
to FlaB-mV, but were seronegative for IgM and IgG binding. For both
peptides, seropositivitywas signiﬁcantly higher for IgM and IgG binding
as compared to IgA (Table 4) [FlaB-mV, IgM-57.9% (77/133) and IgG-
53.4% (71/133) vs. IgA-36.1% (48/133), P ≤ 0.01; C6, IgM-55.6% (74/
133) and IgG-54.1% (72/133) vs. IgA-30.1% (40/133), P ≤ 0.0001]. The
majority of patient sera had positive levels of either IgM or IgG antibod-
ies [C6-88/133 (66.1%); FlaB-mV-89/133 (66.9%), IgM or IgG binding].
The rate of IgA seropositivity to FlaB-mV and C6 in patients who were
also seropositive for IgM or IgG was 53.9% (48/89) and 45.5% (40/88),
respectively. Thus, approximately one-half of patients who were sero-
positive for anti-Bb peptide antibody (as determined by IgM or IgG
binding to the peptides) were also seropositive for IgA.
27.8% (37/133) of patient sera had positive levels of all three anti-
bodies IgA, IgM, and IgG to FlaB-mV. This represented 77.1% (37/48)
of all FlaB-mV IgA seropositive patients, while the remaining 22.9%
(11/48) of FlaB-mV IgA seropositive patients were co-positive for either
IgM [14.6% (7/48)] or IgG [8.3% (4/48)], but not both. 21.8% (29/133) of
patient sera had positive levels of all three antibodies to C6,
representing 72.5% (29/40) of all C6 IgA seropositive patients; the re-
maining 27.5% (11/40) C6 IgA seropositive patients were co-positive
for either IgM [15.0% (6/40)] or IgG [12.5% (5/40)], but not both. There-
fore, positive levels of IgA did not necessarily follow the same pattern as
Fig. 1. IgA binding to FlaB-mV and C6 in patients with early and late LD as compared to healthy and disease controls. IgA binding to FlaB-mV (left panel) and C6 (right panel) following
incubation with serum from patients with early (n = 152) or late LD (n = 19), healthy controls living in regions endemic (n = 35) or nonendemic (n = 104) for LD, or patients
with rheumatoid arthritis (n = 53), syphilis (n = 34), or ﬁbromyalgia (n = 16). Data are presented as absorbance at 450 nm. Dotted lines indicate cut-off for positive (3SD) or
equivocal (2SD) levels of antibody binding. Indicated p values were calculated using a Kruskal-Wallis ANOVA followed by a Dunn's multiple comparison post-test. *p b 0.05, **p b 0.01,
***p ≤ 0.001, ****p b 0.0001.
93C. D'Arco et al. / EBioMedicine 19 (2017) 91–97
observed for IgG, as positive IgA levels were equally associated with
positive IgM and positive IgG levels.
3.3. Clinical Manifestations Associated with IgA-Seropositive Patients
Of the Lyme sera tested, we were able to obtain clinical data for a
total of 83 patients, 64 early LD (28 from the Northeast, and 36 from
the Upper Midwest) and 19 late LD (from the Upper Midwest). Positive
levels of IgA binding to FlaB-mV were observed in 35.7% (10/28) pa-
tients from the Northeast and 69.4% (25/36) patients from the Upper
Midwest. Positive levels of IgA to C6 were observed in 32.1% (9/28) pa-
tients from the Northeast and 63.9% (23/36) patients from the Upper
Midwest. Positive levels of IgM or IgG to FlaB-mV were observed in
64.3% (18/28) of patients from the Northeast, and 100% (36/36) of pa-
tients from the Upper Midwest; seropositivity to C6 was identical. The
rate of positive IgA levels to FlaB-mV and C6 in patients whowere sero-
positive for IgM or IgG in the Northeast was 55.6% (10/18) and 50.0% (9/
18), respectively, and in the Upper Midwest was 69.4% (25/36) and
63.9% (23/36), respectively.
Of the 28 early LD patients from the Northeast, 10 had positive IgA
levels to either FlaB-mV or C6, and 18 sera were negative (Table 5).
Two important clinical features correlated with IgA seropositivity: evi-
dence of disseminated infection, deﬁned as the presence of multiple
EM, reported at the patient's initial visit, and reports of neurological
manifestations (Table S1). Patients with multiple EMwere signiﬁcantly
more likely to be positive for IgA when compared to those with single
EM lesions (p ≤ 0.005) (Table 5). 100% (10/10) of the IgA positive
individuals presented with multiple lesions, as opposed to only 38.9%
(7/18) of IgA negative individuals. A signiﬁcantly greater proportion
(p b 0.05) of the 10 IgA seropositive individuals (5/10, 50.0%) reported
neurologic manifestations and migratory arthralgia, including 7th
nerve palsy (2), acute meningitis (3), balance problems (1), radiculitis
(1), nystagmus (1), and brachial plexus pain (1), or migratory arthral-
gias (1), compared to the 18 seronegative patients (Table 5). Only one
IgA seronegative patient (1/18, 5.6%) had neurologic manifestations.
That patient presented with 7th nerve palsy, but did not present with
an EM lesion and denied any other signiﬁcant symptoms (Table S1).
Other disease manifestations commonly reported in IgA positive
patients included fatigue (100%, 10/10), arthralgia (70.0%, 7/10), stiff
neck (50.0%, 5/10), myalgia (50.0%, 5/10), and headache (50.0%, 5/10).
There was signiﬁcantly less fatigue reported (50%, 9/18, p b 0.01) by
the IgA negative patients. The rates of arthralgia (33.3%, 6/18), stiff
neck (11.1%, 2/18), myalgia (27.8%, 5/18) and headache (33.3%, 6/18)
were also reported less frequently in IgA negative patients, but not sig-
niﬁcantly so. Dizziness and tingling were also reported, but at similar
rates in both IgA-positive and -negative individuals. IgA positive and
negative patients reported a similar duration of EM prior to their initial
visit (4.3 days± 2.3 vs. 4.7 days± 2.5, respectively [note: the single pa-
tient reporting an EM onset of 60 days prior to ﬁrst visit was not includ-
ed in this calculation, as this was N23 SD from the mean of all other
patients and was treated as an outlier]).
Wewere able to obtain clinical data on 36patientswith early disease
and 19 patientswith late disease from theUpperMidwest (Table S2). Of
the 36 early LD sera, 27 were IgA seropositive, 2 were equivocal, and 7
were seronegative for binding to either FlaB-mV or C6. In the IgA posi-
tive patients, the most common reported manifestations were myalgia
(51.9%, 14/27), fever (37.0%, 10/27), headache (37.0%, 10/27), fatigue/
lethargy/malaise (29.6%, 8/27), and arthralgia (22.2%, 6/27) (Table S2).
The two IgA equivocal patients reported arthralgia (100%, 2/2), myalgia
(50%, 1/2), fever (50%, 1/2), and headache (50%, 1/2). By comparison,
IgA negative early LD patients reported fatigue (42.8%, 3/7), headache
(28.6%, 2/7), fever (14.3%, 1/7), arthralgia (14.3%, 1/7), and myalgia
(14.3%, 1/7) (Table S2). Althoughmyalgia, fever, headache, and arthral-
gia were more common in IgA positive patients compared to IgA nega-
tive patients, this did not reach statistical signiﬁcance. Only one of 38
patients reported a distinct neurological sign, diplopia, and another
was reported as having ‘possibly CNS involvement’; both were IgA pos-
itive (Table S2). Only one patient from the Upper Midwest hadmultiple
EM and was IgA positive (Table S2). Reported duration of symptoms in
patients from the Upper Midwest was 16.8 days ± 12.0; though, values
were only available for a limited number of patients (Table S2). Compar-
isons of duration of symptoms between IgA positive and IgA negative
patients in the Upper Midwest could not be drawn. Late LD patients re-
ported common signs of arthritis (joint pain, swelling) regardless of
their IgA levels (Table S2).
4. Discussion
This is a study of IgA seroreactivity to Bb antigens in a large group of
early LD patients; we are unaware of any previous studies that have fo-
cused on anti-Bb IgA in early LD. As EMdevelops between 3 and 30 days
after a tick bite (average of 7 days), the level of anti-Borrelia antibody
within this patient population can vary greatly (Berger, 1993). Depend-
ing upon when patients seek medical attention, they may present with
IgM, IgG, or a mixture of both to Bb. In the present study, we report sig-
niﬁcant levels of antigen-speciﬁc serum IgA in approximately one-third
Table 2
IgA seroreactivity to FlaB-mV or C6.
FlaB-mVa C6b
Diagnosis Positive Equivocal Negative Total Positive Equivocal Negative Total
Early Lyme (n= 152) 53 (34.9%) 5 (3.3%) 94 (61.8%) 152 43 (28.3%) 11 (7.2%) 98 (64.5%) 152
Late Lyme (n= 19) 6 (31.6%) 2 (10.5%) 11 (57.9%) 19 3 (15.8%) 2 (10.5%) 14 (73.7%) 19
Normal (non-endemic) (n= 104) 1 (0.9%) 3 (2.8%) 100 (96.2%) 104 1 (0.9%) 3 (2.8%) 100 (96.2%) 104
Normal (endemic) (n= 35) 1 (2.9%) 2 (5.7%) 32 (91.4%) 35 1 (2.9%) 1 (2.9%) 33 (94.3%) 35
Rheumatoid arthritis (n= 53) 0 (0.0%) 1 (1.9%) 52 (98.1%) 53 1 (1.9%) 0 (0.0%) 52 (98.1%) 53
Syphilis (n= 34) 1 (2.9%) 2 (5.9%) 31 (91.2%) 34 1 (2.9%) 0 (0.0%) 33 (97.1%) 34
Fibromyalgia (n= 16) 0 (0.0%) 0 (0.0%) 16 (100.0%) 16 0 (0.0%) 0 (0.0%) 16 (100.0%) 16
a Fisher's exact test of positive vs. non-positive (equivocal + negative) IgA levels (alpha b 0.05) for each indicated group: early Lyme vs. nonendemic normals (p b 0.0001); early Lyme
vs. endemic normals (p b 0.0001); early Lyme vs. syphilis (p b 0.0001); early Lyme vs. RA (p b 0.0001); early Lyme vs. ﬁbromyalgia (p b 0.005), early Lyme vs. late Lyme n.s.; late Lyme vs.
nonendemic normals (p b 0.0001).; late Lyme vs. endemic normals (p b 0.01).; late Lyme vs. syphilis (p b 0.01); late Lyme vs. RA (p b 0.005); late Lyme vs.ﬁbromyalgia (p b 0.05). n.s.=not
signiﬁcant.
b Fisher's exact test of positive vs. non-positive (equivocal + negative) IgA levels (alpha b 0.05) for each indicated group: early Lyme vs. nonendemic normals (p b 0.0001); early Lyme
vs. endemic normals (p b 0.001); early Lyme vs. syphilis (p b 0.001); early Lyme vs. RA (p b 0.0001); early Lyme vs. ﬁbromyalgia (p b 0.05); early Lyme vs. late Lyme n.s; late Lyme vs.
nonendemic normals (p b 0.05); late Lyme vs. endemic normals n.s.; late Lyme vs. syphilis n.s.; late Lyme vs. RA n.s.; late Lyme vs. ﬁbromyalgia n.s. n.s. = not signiﬁcant.
Table 3
Sensitivity and speciﬁcity for anti-FlaB-mV and anti-C6 IgA in early Lyme disease.
FlaB-mV C6
Sensitivity %a 34.9 28.3
Speciﬁcity %a 98.8 98.4
Likelihood Ratioa 28.1 17.1
a Values were calculated comparing positive IgA levels to non-positive IgA levels
(equivocal + negative detection) of early LD patients (n = 152) vs. all negative
control patients (n = 242).
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of total patients diagnosed with early LD. When IgA seropositivity was
evaluated in the context of existing IgM/IgG seropositivity, ~50% of pa-
tients who were seropositive for anti-FlaB-mV or anti-C6 IgM or IgG
were also seropositive for IgA. The lower rate of IgA binding in the
total early LD population may simply be due to the fact that some of
the patients had not seroconverted at the time of initial blood draw.
We expect that this IgA is monomeric, as the majority of circulating
serum IgA in humans is monomeric, and of the IgA1 subtype; however,
we did not conﬁrm this in our studies. We assessed IgA binding to two
speciﬁc immunogenic peptides derived from Bb antigens, C6 and FlaB-
mV.We chose to use these peptides rather than whole protein antigens
to minimize the possibility of IgA binding to cross reactive epitopes.
Concomitantly, very little cross-reactivity was observed in healthy and
disease control patients in terms of anti-C6 and -FlaB-mV IgA levels.
Sensitivity of IgA binding to FlaB-mV was slightly better than binding
to C6, which is unsurprising considering that this peptide contains
two epitopes from two different antigens, VlsE and ﬂagellum, where
C6 contains only one epitope from a single antigen, VlsE (Gomes-
Solecki et al., 2007).
The function of IgA in LD is unclear; however, the role of serum IgA in
systemic immune responses in general is poorly understood in compar-
ison to the roles of IgM and IgG. It is primarily regarded as a neutralizing
antibody when produced in polymeric form at mucosal surfaces, where
it is secreted across the mucosal barrier. The role of IgA in LD has been
poorly studied, presumably because Bb is not associated with mucosal
pathogenesis. We are aware of only one study, from 1979, that mea-
sured anti-Bb IgA levels in patients with early disease (Steere et al.,
1979); however, anti-Bb IgA was incidental to the focus of the study.
It indicated that anti-Bb IgA was present and appeared to increase
alongwith the level of anti-Bb IgG and that both IgA and IgGmoved con-
versely to anti-Bb IgM. IgAproduction in LDhas principally been studied
in terms of the production of intrathecal IgA speciﬁc to Bb antigens dur-
ing Lymeneuroborreliosis, a late stage formof the disease (Kaiser, 1998;
Steere et al., 1990; Jesse et al., 2011; Schwenkenbecher et al., 2017;
Kowarik et al., 2012; Roberg et al., 1995; Steere et al., 1990; Jesse
et al., 2011; Schwenkenbecher et al., 2017; Kowarik et al., 2012). High
antigen-speciﬁc intrathecal IgA levels are also typical of tuberculosis
meningitis, which is often included in the differential diagnosis with
Lyme neuroborreliosis, as both diseases are marked by abnormal cere-
bral spinal ﬂuid (CSF) changes in immunoglobulins that include elevat-
ed intrathecal IgM, elevated B-speciﬁc antibody indexes for IgG or IgM,
lymphopleocytosis, severe blood-CSF barrier dysfunction, and intrathe-
cal IgA (Djukic et al., 2012). Conversely, intrathecal synthesis of IgG is
observed in multiple sclerosis (MS), an autoimmune disease (Reiber,
1998). This suggests a potential biological role for intrathecal IgA in in-
fectious disease, and provides limited insight into a possible neurologic
function of IgA.
The results of this study suggest an association between serum anti-
Bb IgA and disseminated infection (multiple EM), and possibly neuro-
logic manifestations or arthralgia. IgA-positive patients from the North-
east were signiﬁcantly more likely to have multiple EM lesions,
neurologic manifestations or migratory polyarthralgia when compared
to IgA negative patients from the Northeast. In fact, all 10 IgA positive
patients in this population, for which clinical data was available, pre-
sented with multiple EM. The rate of multiple EM in patients from the
northeast was quite high (60.7%, 17/28); however, this could be the re-
sult of multiple EM patients preferentially seeking care at a specialty LD
clinic rather than their primary care physician. Only one patient from
the Upper Midwest presented with a deﬁned neurological sign, and an-
other with possible CNS involvement, but both were IgA positive. The
remaining IgA positive patients from the Upper Midwest reported
less-speciﬁc complaints including myalgia, arthralgia, headache, and
fever. Similar to patients from the Northeast, these less-speciﬁc com-
plaints were reported more often in IgA positive early LD patients;
though these differences were not statistically signiﬁcant compared to
IgA negative early LD patients. The small number of IgA negative pa-
tients in this groupmay have contributed to the lack of statistical differ-
ences. The differences in IgA/neurological symptom association
observed between IgA positive patients in the Northeast and Upper
Midwest could be due to a number of factors, including but not limited
to: regional differences in Bb strains, differences in reportingpractices of
diagnosing clinicians, differences in patient referral patterns, or regional
differences in Lyme pathology, presentation, and progression. The sam-
ple size of the current study is not large enough to evaluate these vari-
ous factors; a larger prospective study is being designed to further
assess these results.
Table 4
Proportion of positive, equivocal, and negative anti-FlaB-mV and anti-C6 IgA, IgM, and IgG in early Lyme patients (n= 133).
FlaB-mVa C6
Test
Result
IgAb IgM IgG All three IgM+ or
IgG+c
IgA in IgM/IgG+
patientsd
IgAe IgM IgG All three IgM+ or
IgG+c
IgA in
IgM/IgG+
patientsd
Positive 36.1% (48) 57.9% (77) 53.4% (71) 27.8%f (37) 66.9% (89) 53.9% (48/89) 30.1% (40) 55.6% (74) 54.1% (72) 21.8%f (29) 66.1% (88) 45.5% (40/88)
Equivocal 3.8% (5) 6.0% (8) 4.5% (6) 5.3%g (7) 4.5% (6) 7.5% (10) 5.3% (7) 6.0% (8) 10.5%g (14) 3.8% (5)
Negative 60.2% (80) 36.1% (48) 42.1% (56) 66.9%h (89) 28.6% (38) 62.4% (83) 39.1% (52) 39.9% (53) 67.6%h (90) 30.1% (40)
a All percentages listed in this table are out of the total number of early Lyme patients for which there was IgA, IgM, and IgG data (n= 133).
b Fisher's exact test of positive vs. non-positive (equivocal + negative) IgA levels (alpha b 0.05) for each indicated group: IgA vs. IgM binding (p b 0.001); IgA vs. IgG binding (p b 0.01),
FlaB-mV.
c Positive, equivocal, or negative levels of IgM only, IgG only, or both IgM and IgG.
d Positive levels of IgA only in sera that were seropositive for IgM, IgG, or IgM + IgG.
e Fisher's exact test of positive vs. non-positive (equivocal + negative) IgA levels (alpha b 0.05) for each indicated group: IgA vs. IgM binding (p b 0.0001); IgA vs. IgG binding
(p b 0.0001), C6.
f Positive levels of IgM, IgG, and IgA binding to a peptide.
g A combination of positive and equivocal levels of IgM, IgG, and IgA binding to a peptide, no negative levels of any isotype.
h Negative levels for binding of peptide to at least one antibody isotype.
Table 5
Comparison of clinical manifestations reported in Northeastern US early Lyme disease pa-
tients (n= 28).
Test Result
Proportion of patients
with multiple EMa
Proportion of patients with neurological or
polymigratory related manifestationsb
IgA Positive 10 out of 10 (100.0%) 5 out of 10 (50.0%)
IgA Negative 7 out of 18 (38.9%) 1 out of 18 (5.6%)
a p b 0.005, IgA positive vs. IgA negative patients calculated using a Fisher's exact test
(alpha b 0.05).
b p b 0.05, IgA positive vs. IgA negative patients calculated using a Fisher's exact test
(alpha b 0.05).
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The rate of IgA seropositivity was signiﬁcantly higher in patients
from the Upper Midwest compared to the Northeast (p b 0.005). How-
ever, the rate of seropositivity for IgM/IgG was also signiﬁcantly higher
in patients from the Upper Midwest (p b 0.0001), suggesting that the
lower IgA seropositivity could be linked to a lower rate of seroconver-
sion in early LD patients from the Northeast compared to the Upper
Midwest. Concordantly, when IgA seropositivity was evaluated as a
function of IgM/IgG seropositivity, the positive levels of IgA to either
FlaB-mV or C6 was much closer in patients from the two regions. The
difference in seroconversion between the two regions may lie in differ-
ences in the duration of illness prior to diagnosis. Though data was only
obtained for some patients from the Upper Midwest, the available data
suggests that duration of illness prior to diagnosis was far shorter in pa-
tients from the Northeast (4.6 days ± 2.4) compared to the Upper Mid-
west (16.8 days ± 12.0). It should be noted that Northeastern patient
data reported duration of EM prior to diagnosis, while Midwestern pa-
tient data reported duration of symptoms prior to diagnosis, which
could exist prior to development of EM; however, the data still imply
a trend toward a longer time of infection prior to seeking medical
care. On the other hand, the late LD patients from the Midwest had, as
expected, a very high rate of IgG seropositivity (94.7% (18/19) with
5.3% equivocal (1/19) and no negative), but a lower rate of seropositive
IgA individuals (31.6%, 6/19), compared to patients with early LD.
Therefore, duration of illness does not seem to be a sole driving factor
in IgA seropositivity in LD, suggesting that additional factors contribute
to the induction of anti-Bb IgA, though at the current time these factors
remain undeﬁned. No speciﬁc associations between IgA positivity and
reported clinical manifestations in the Lyme arthritis population were
observed, and we unfortunately did not have access to a bank of
serum from patients with Lyme neuroborreliosis. A larger prospective
study, based upon our ﬁndings, is being designed to further assess the
association of anti-Borrelia IgA with speciﬁc clinical disease
manifestations.
Our data provides some evidence that suggests individuals with a
high anti-Bb IgA index could be a subpopulationwith unique character-
istics that represents roughly half of all LD-seropositive patients; how-
ever, limitations within this study prevent drawing ﬁrm conclusions
based upon our data. The limitations of this study are that we do not
have access to detailed clinical information on all 152 of the patients.
As this is a retrospective study using stored serum collected from mul-
tiple sites over many LD seasons, differences in reporting practices at
different sites also limited the usefulness of available patient informa-
tion. This resulted in a smaller overall number of IgA positive patients
for which correlations could be drawn. We also did not have access to
additional laboratory measurements (if any) such as lumbar puncture
for neurological disease to deﬁnitively conﬁrm disseminated LD, and
draw comparisons between potential systemic and intrathecal IgA pro-
duction. We also did not have access to a patient population with de-
ﬁned Lyme neuroborreliosis to draw comparisons. We are currently
designing a prospective study to further analyze the production of Bb-
speciﬁc IgA in patients during early LD at both acute and convalescent
patient visits to assess the induction of anti-Bb IgA over the course of
infection.
Here, we present evidence that a substantial population of individ-
ualswith early LDproduce high levels of circulating anti-Bb IgA.Wheth-
er anti-Bb serum IgA can provide prognostic value for the development
of disseminated disease or neurological symptoms, and whether the
evaluation of anti-Bb IgA levels would provide a clinical beneﬁt, are
questions that deserve further study.
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